Codice QR

Efficacy of galcanezumab in migraine central sensitization

Abstract Galcanezumab, a monoclonal antibody targeting the calcitonin gene-related peptide pathway (CGRP mAb), acts peripherally due to its large size. However, recent studies have suggested that CGRP mAbs may also have a central mode of action. This study aimed to evaluate the central effects of ga...

Descrizione completa

Salvato in:
Autori principali: Daisuke Danno, Noboru Imai, Shigekazu Kitamura, Kumiko Ishizaki, Shoji Kikui, Takao Takeshima
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Portfolio 2024-09-01
Serie:Scientific Reports
Soggetti:
Migraine
Central sensitization
CGRP antibodies
Galcanezumab
Central effect
Interictal burden
Accesso online:https://doi.org/10.1038/s41598-024-72282-6
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi